Zynerba Pharmaceuticals, Inc. Price Today
Zynerba Pharmaceuticals, Inc.
ZYNE
Healthcare
$18.94M
💰
Market Cap
0
💸
Price to Earnings
$-0.8
🎉
EPS
+0
🌳
ESG
Consensus Recommendations
Buy Consensus
Buy |
3 |
Strong Buy |
4 |
Hold |
2 |
Sell |
0 |
Strong Sell |
0 |
ZYNE Price Forecast Target
0.4 👉 10.0 +2733%
ZYNE EPS Forecast
-0.8 👉 -0.6 +-25%
Financials
Profit Margin
0 %
Revenue Growth
0 %
Dividend
$ 0
Held Percent
6.1% - Insiders
12.1% - Institutions
81.8% - Public
Major Fund Holders
-
💰 Vanguard Group Inc $937,228.0
-
💰 Blackrock Inc. $360,641.0
-
💰 ETF Managers Group, LLC $310,954.0
-
💰 Renaissance Technologies, LLC $244,971.0
-
💰 Millennium Management Llc $196,230.0
Stock Ideas
Elon Musk Portfolio
Enter the visionary world of Elon Musk, a name that needs no introduction in the realms of innovation, entrepreneurship, and technology. With a trailblazing spirit and an unyielding drive, Musk has become a household name, propelling himself to extr…
Andreas Halvorsen Portfolio
Andreas Halvorsen is a Norwegian billionaire investor, hedge fund manager, and the founder of Viking Global Investors, a large hedge fund with over $50 billion in assets under management. He is known for his long-term, value-oriented investment appr…
Steven Cohen Portfolio
Steven Cohen, the legendary trader and billionaire founder of Stamford-based SAC Capital, has established himself as a force to be reckoned with in the hedge fund industry. With a staggering net worth of $8 billion and an impressive $14 billion in …
Stanley Druckenmiller Portfolio
Stanley Druckenmiller is a legendary hedge fund manager who has made billions of dollars for his investors. His current portfolio is heavily invested in gold, silver, and other precious metals. He also owns shares in several technology and healthcar…📮FAQ
Some Frequently Asked Questions.
The Zynerba Pharmaceuticals, Inc. industry is Drug Manufacturers—Specialty & Generic
The Zynerba Pharmaceuticals, Inc. sector is Healthcare
The Zynerba Pharmaceuticals, Inc. forecasted predicted Price to Earnings PE ratio is -0.6
The Zynerba Pharmaceuticals, Inc. Price to Earnings PE ratio is 0
The Market Capitalization of Zynerba Pharmaceuticals, Inc. is $18.94M
There are total of 46681585 float shares with 12.1% held by Institutions and 6.1% held by insiders
The MZynerba Pharmaceuticals, Inc. forecasted Earnings per Share EPS is $-0.6
The Zynerba Pharmaceuticals, Inc. Earnings per Share EPS is -0.8
The Zynerba Pharmaceuticals, Inc. company has $0 gross profits with 0 profit margins
The Zynerba Pharmaceuticals, Inc. Earnings Growth is 0% with 0% quarterly earnings growth
The Zynerba Pharmaceuticals, Inc. Revenue is $0 with 0 revenue growth
The price target for Zynerba Pharmaceuticals, Inc. stock is $10.0 for the high target and $0.4 for the low target
The consensus analyst recommendations for Zynerba Pharmaceuticals, Inc. is Buy, however the decision to buy or sell the stock should be entirely yours, as you are earning your own money and hence responsible on how to allocate and spend them.
The consensus analyst recommendations for Zynerba Pharmaceuticals, Inc. is Buy, with the following breakdown:
- Buy: 3
- Strong Buy: 4
- Hold: 2
- Sell: 0
- Strong Sell: 0
The Beta of Zynerba Pharmaceuticals, Inc. is 1.8
The dividend of Zynerba Pharmaceuticals, Inc. is $0
The dividend yield of Zynerba Pharmaceuticals, Inc. is 0%
The biggest institutional and mutual fund holders of Zynerba Pharmaceuticals, Inc. stock are
- Vanguard Group Inc
- Blackrock Inc.
- ETF Managers Group, LLC
- Renaissance Technologies, LLC
The Zynerba Pharmaceuticals, Inc. ESG Score is 0, with the following breakdown:
- E: 0
- S: 0
- G: 0